A Phase 3 interventional study of IR CD-LD and IPX203 ER CD-LD in Parkinson's Disease (Disorder), sponsored by Impax Laboratories, LLC. Completed at 108 sites in 8 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2023-02-09.
Sponsored by Impax Laboratories, LLC (part of Amneal Pharmaceuticals, Inc.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Parkinson Disease by Amneal Pharmaceuticals, Inc. — 1 open to participants now, 1 under way, none of them phase 3. Parkinson Disease · Amneal Pharmaceuticals, Inc..
Among the 14 studies in Parkinson Disease by Amneal Pharmaceuticals, Inc., this one has the largest enrollment, is the only one that started in 2018, is one of 7 in phase 3, and was the 12th registered.
4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.
Browse Parkinson Disease studies →1 of the 14 studies in Parkinson Disease by Amneal Pharmaceuticals, Inc. is open now, in 1 country. Recruiting first, the newest first:
Impax Laboratories, LLC · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 6 · Phase 3 7 · Phase 4 1
First in 2005; this study’s year is marked. 1 started in 2018.
This study's enrollment of 630 is above the median of 40 across 3,357 interventional studies indexed under Parkinson Disease.
Median enrollment 77 across the 14 interventional studies. Of the 13 that completed or were terminated, 9 (69%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Impax Laboratories, LLC, one of the names counted as Amneal Pharmaceuticals, Inc.. Under that name alone:
Impax Laboratories, LLC is the lead sponsor of 20 studies on the registry; 1 is open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 2 (25%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 14 studies in Parkinson Disease by Amneal Pharmaceuticals, Inc., from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To evaluate the safety and efficacy of IPX203 (carbidopa and levodopa) extended-release capsules (IPX203 ER CD-LD) in comparison to immediate release (IR) CD-LD in the treatment of CD-LD-experienced participants with Parkinson's disease (PD) who have motor fluctuations.
This was a multicenter, randomized, double-blind, double-dummy, active-controlled, parallel-group study. The study consisted of a 3-week, open-label IR CD-LD dose adjustment period; a 4-week, open-label period for conversion to IPX203; followed by a 13-week double-blind treatment period with participants randomized in a 1:1 ratio, stratified by center, to receive either IPX203 (with matching IR CD-LD placebo) or IR CD-LD (with matching IPX203 placebo).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants started on the same dose as the pre-study dosing regimen of IR CD-LD and then received dose adjusted IR CD-LD tablets daily orally, for a period of 3 weeks. If the participant was taking controlled release carbidopa-levodopa (CR CD-LD), the CR CD-LD was discontinued and substituted with a 1:1 milligram-equivalent dose of IR CD-LD.
Drug: IR CD-LD
Participants received extended release (ER) CD-LD (IPX203) capsules orally, every 6 - 12 hours for a period of 4 weeks at a dose based on their most frequent stable dose of IR CD-LD in dose adjustment period. Participant with most frequent stable dose of 25-100 milligrams (mg) IR CD-LD received 70 - 280 mg IPX203 thrice daily (TID); \>25-100 - 37.5-150 mg IR CD-LD received 105-420 mg IPX203 TID; \>37.5-150 - 50-200 mg IR CD-LD received 140-560 mg IPX203 TID; \>50 - 200 mg IR CD-LD received 175-700 mg IPX203 TID. Participants who received a daily total dose of less than 125-500 mg IR CD-LD in dose adjustment received IPX203 every 12 hours. After initial dose conversion from IR CD-LD to IPX203 as per above mentioned dose conversion schedule, the dose of IPX203 could be further adjusted during the 4 week dose conversion period.
Drug: IPX203 ER CD-LD
Participants received IPX203 capsules orally, every 6 - 12 hours for 13 weeks at a stable dose established at the end of dose conversion period along with placebo matched to IR CD-LD.
Drug: IPX203 ER CD-LD · Other: Placebo Matching IPX203
Participants received IR CD-LD tablets daily orally, for 13 weeks at a stable dose established at the end of dose adjustment period along with placebo matched to IPX203.
Drug: IR CD-LD · Other: Placebo Matching IR CD-LD
Active comparator - IR CD-LD
Also known as: Generic for Sinemet tablets
Investigational formulation - ER CD-LD
Double dummy placebo capsules
Double dummy placebo tablets
Mean Change From Baseline in "Good on" Time Per Day at Week 20/Early Termination (ET)
"Good on" time was derived from the 3-day PD Diaries. For each day, "Good on" time was calculated by adding the number of half-hour intervals in which either an "On" without dyskinesia or "On" with nontroublesome dyskinesia was checked. Baseline was defined as data obtained from PD Diary collected over 3 days prior to Week 7/Randomization. Least square mean (LSM), standard error (SE), confidence interval (CI), Mixed model repeated measures (MMRM), Change from baseline (CFB).
Time frame: Baseline (Week 7) and Week 20/ET
Change From Baseline in "Off" Time Per Day at Week 20/ET
"Off" time was derived from the 3-day PD Diaries. For each day, "Off" time was calculated by adding the number of half-hour intervals in which the Status "Off" was checked. Baseline was defined as data obtained from PD Diary collected over 3 days prior to Week 7/Randomization.
Time frame: Baseline (Week 7) and Week 20/ET
Percentage of Participants With Either "Much Improved" or "Very Much Improved" in Patient Global Impression of Change (PGI-C) Scores at Week 20/ET
The Patient Global Impression of Change (PGIC) is self assessment questionnaire which was used by participants to compare his/her condition on a 7-point scale ranging from 1-Very Much Worse, 2-Much Worse, 3-Minimally Worse, 4-No Change, 5-Minimally Improved, 6-Much Improved, 7-Very Much Improved. Percentage of participants with either "Much Improved" or "Very Much Improved" was reported.
Time frame: Week 20/ET
Change From Baseline in The Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III at Week 20/ET
MDS-UPDRS is a multimodal scale assessing impairment and disability consisting of 4 parts. (Part I; 13 items) non-motor experiences of daily living, (Part II; 13 items) motor experiences of daily living completed by the participants, (Part III; 34 items) motor examination of PD and was administered by the rater, and (Part IV; 6 items) motor complication integrates participant-derived information with the rater's clinical observations and judgements and is completed by the rater. For each question a numeric score was assigned between 0-4, where 0 = Normal, 1 = Slight, 2 = Mild, 3 = Moderate, 4 = Severe. MDS-UPDRS Total Score equals the sum of Parts I, II, and III and IV (Range 0-234). Part III score ranges from 0 to 136. A higher score indicated more severe symptoms of PD. Baseline was defined as data obtained from PD Diary collected over 3 days prior to Week 7/Randomization.
Time frame: Baseline (Week 7) and Week 20/ET
Change From Baseline in The Sum of MDS-UPDRS Part II and Part III at Week 20/ET
MDS-UPDRS is a multimodal scale assessing impairment and disability consisting of 4 parts. (Part I; 13 items) non-motor experiences of daily living, (Part II; 13 items) motor experiences of daily living completed by the participants, (Part III; 34 items) motor examination of PD and was administered by the rater, and (Part IV; 6 items) motor complication integrates participant-derived information with the rater's clinical observations and judgements and is completed by the rater. For each question a numeric score was assigned between 0-4, where 0 = Normal, 1 = Slight, 2 = Mild, 3 = Moderate, 4 = Severe. MDS-UPDRS Total Score equals the sum of Parts I, II, and III and IV (Range 0-234). The scale range for Part II+III score is 0-188. A higher score indicated more severe symptoms of PD. Baseline was defined as data obtained from PD Diary collected over 3 days prior to Week 7/Randomization.
Time frame: Baseline (Week 7) and Week 20/ET
A total of 630 enrolled participants entered the immediate release carbidopa-levodopa (IR CD-LD) dose adjustment period of which 589 participants entered IPX203 conversion period of which 506 participants entered double-blind maintenance period. Participants were randomized in a 1:1 ratio in double blind period.
| Milestone | IR CD-LD - Dose Adjustment | IPX203 - Dose Conversion | IPX203 - Double-Blind Maintenance | IR CD-LD - Double -Blind Maintenance |
|---|---|---|---|---|
| Started | 630 | 0 | 0 | 0 |
| Completed | 589 | 0 | 0 | 0 |
| Not completed | 41 | 0 | 0 | 0 |
| Withdrew: Adverse event | 4 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 1 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 6 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 9 | 0 | 0 | 0 |
| Withdrew: Miscellaneous | 21 | 0 | 0 | 0 |
| Milestone | IR CD-LD - Dose Adjustment | IPX203 - Dose Conversion | IPX203 - Double-Blind Maintenance | IR CD-LD - Double -Blind Maintenance |
|---|---|---|---|---|
| Started | 0 | 589 | 0 | 0 |
| Completed | 0 | 506 | 0 | 0 |
| Not completed | 0 | 83 | 0 | 0 |
| Withdrew: Adverse event | 0 | 35 | 0 | 0 |
| Withdrew: Lack of efficacy | 0 | 10 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 1 | 0 | 0 |
| Withdrew: Non compliance | 0 | 2 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 32 | 0 | 0 |
| Withdrew: Miscellaneous | 0 | 2 | 0 | 0 |
| Milestone | IR CD-LD - Dose Adjustment | IPX203 - Dose Conversion | IPX203 - Double-Blind Maintenance | IR CD-LD - Double -Blind Maintenance |
|---|---|---|---|---|
| Started | 0 | 0 | 256 | 250 |
| Completed | 0 | 0 | 222 | 227 |
| Not completed | 0 | 0 | 34 | 23 |
| Withdrew: Adverse event | 0 | 0 | 14 | 3 |
| Withdrew: Lack of efficacy | 0 | 0 | 5 | 8 |
| Withdrew: Protocol violation | 0 | 0 | 3 | 1 |
| Withdrew: Non compliance | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 10 | 11 |
| Withdrew: Miscellaneous | 0 | 0 | 1 | 0 |
"Good on" time was derived from the 3-day PD Diaries. For each day, "Good on" time was calculated by adding the number of half-hour intervals in which either an "On" without dyskinesia or "On" with nontroublesome dyskinesia was checked. Baseline was defined as data obtained from PD Diary collected over 3 days prior to Week 7/Randomization. Least square mean (LSM), standard error (SE), confidence interval (CI), Mixed model repeated measures (MMRM), Change from baseline (CFB).
| hours/day | IPX203 - Double-Blind Maintenance | IR CD-LD - Double -Blind Maintenance |
|---|---|---|
| Baseline (Week 7) | 11.67 ± 2.943 | 11.72 ± 2.759 |
| Change at Week 20/ET | -0.39 ± 2.706 | -0.97 ± 3.081 |
"Off" time was derived from the 3-day PD Diaries. For each day, "Off" time was calculated by adding the number of half-hour intervals in which the Status "Off" was checked. Baseline was defined as data obtained from PD Diary collected over 3 days prior to Week 7/Randomization.
| hours/day | IPX203 - Double-Blind Maintenance | IR CD-LD - Double -Blind Maintenance |
|---|---|---|
| Baseline (Week 7) | 3.95 ± 2.524 | 4.02 ± 2.466 |
| Change at Week 20/ET | 0.29 ± 2.235 | 0.76 ± 2.901 |
The Patient Global Impression of Change (PGIC) is self assessment questionnaire which was used by participants to compare his/her condition on a 7-point scale ranging from 1-Very Much Worse, 2-Much Worse, 3-Minimally Worse, 4-No Change, 5-Minimally Improved, 6-Much Improved, 7-Very Much Improved. Percentage of participants with either "Much Improved" or "Very Much Improved" was reported.
| percentage of participants | IPX203 - Double-Blind Maintenance | IR CD-LD - Double -Blind Maintenance |
|---|---|---|
| Percentage of Participants With Either "Much Improved" or "Very Much Improved" in Patient Global Impression of Change (PGI-C) Scores at Week 20/ET | 29.7 | 18.8 |
MDS-UPDRS is a multimodal scale assessing impairment and disability consisting of 4 parts. (Part I; 13 items) non-motor experiences of daily living, (Part II; 13 items) motor experiences of daily living completed by the participants, (Part III; 34 items) motor examination of PD and was administered by the rater, and (Part IV; 6 items) motor complication integrates participant-derived information with the rater's clinical observations and judgements and is completed by the rater. For each question a numeric score was assigned between 0-4, where 0 = Normal, 1 = Slight, 2 = Mild, 3 = Moderate, 4 = Severe. MDS-UPDRS Total Score equals the sum of Parts I, II, and III and IV (Range 0-234). Part III score ranges from 0 to 136. A higher score indicated more severe symptoms of PD. Baseline was defined as data obtained from PD Diary collected over 3 days prior to Week 7/Randomization.
| score on a scale | IPX203 - Double-Blind Maintenance | IR CD-LD - Double -Blind Maintenance |
|---|---|---|
| Baseline (Week 7) | 26.9 ± 16.62 | 27.0 ± 16.83 |
| Change at Week 20/ET | 1.1 ± 11.07 | 0.9 ± 10.10 |
MDS-UPDRS is a multimodal scale assessing impairment and disability consisting of 4 parts. (Part I; 13 items) non-motor experiences of daily living, (Part II; 13 items) motor experiences of daily living completed by the participants, (Part III; 34 items) motor examination of PD and was administered by the rater, and (Part IV; 6 items) motor complication integrates participant-derived information with the rater's clinical observations and judgements and is completed by the rater. For each question a numeric score was assigned between 0-4, where 0 = Normal, 1 = Slight, 2 = Mild, 3 = Moderate, 4 = Severe. MDS-UPDRS Total Score equals the sum of Parts I, II, and III and IV (Range 0-234). The scale range for Part II+III score is 0-188. A higher score indicated more severe symptoms of PD. Baseline was defined as data obtained from PD Diary collected over 3 days prior to Week 7/Randomization.
| score on a scale | IPX203 - Double-Blind Maintenance | IR CD-LD - Double -Blind Maintenance |
|---|---|---|
| Baseline (Week 7) | 38.9 ± 22.20 | 39.3 ± 21.65 |
| Change at Week 20/ET | 2.0 ± 13.54 | 1.8 ± 12.39 |
Collected over From first dose up to 30 days after last dose (Up to Weeks 24). Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| IR CD-LD - Dose Adjustment | 0/630 (0%) | 7/630 (1.1%) | 40/630 (6.3%) |
| IPX203 - Dose Conversion | 0/589 (0%) | 12/589 (2%) | 130/589 (22.1%) |
| IPX203 - Double-Blind Maintenance | 0/256 (0%) | 8/256 (3.1%) | 35/256 (13.7%) |
| IR CD-LD - Double -Blind Maintenance | 0/250 (0%) | 4/250 (1.6%) | 32/250 (12.8%) |
| Event | IR CD-LD - Dose Adjustment | IPX203 - Dose Conversion | IPX203 - Double-Blind Maintenance | IR CD-LD - Double -Blind Maintenance |
|---|---|---|---|---|
| Atrioventricular block completeCardiac disorders | 0/630 | 0/589 | 0/256 | 1/250 |
| Cardiac failureCardiac disorders | 0/630 | 0/589 | 0/256 | 1/250 |
| Urinary tract infectionInfections and infestations | 0/630 | 1/589 | 0/256 | 1/250 |
| Back painMusculoskeletal and connective tissue disorders | 0/630 | 0/589 | 0/256 | 1/250 |
| Benign prostatic hyperplasiaReproductive system and breast disorders | 0/630 | 0/589 | 0/256 | 1/250 |
| BradycardiaCardiac disorders | 0/630 | 0/589 | 1/256 | 0/250 |
| AstheniaGeneral disorders | 0/630 | 0/589 | 1/256 | 0/250 |
| FatigueGeneral disorders | 0/630 | 0/589 | 1/256 | 0/250 |
| PyelonephritisInfections and infestations | 0/630 | 0/589 | 1/256 | 0/250 |
| Ejection fraction descreasedInvestigations | 0/630 | 0/589 | 1/256 | 0/250 |
| Event | IR CD-LD - Dose Adjustment | IPX203 - Dose Conversion | IPX203 - Double-Blind Maintenance | IR CD-LD - Double -Blind Maintenance |
|---|---|---|---|---|
| DyskinesiaNervous system disorders | 11/630 | 40/589 | 5/256 | 1/250 |
| NauseaGastrointestinal disorders | 7/630 | 29/589 | 11/256 | 2/250 |
| Dry mouthGastrointestinal disorders | 2/630 | 25/589 | 3/256 | 2/250 |
| FallInjury, poisoning and procedural complications | 6/630 | 13/589 | 5/256 | 9/250 |
| Urinary tract infectionInfections and infestations | 1/630 | 7/589 | 4/256 | 8/250 |
| DizzinessNervous system disorders | 3/630 | 17/589 | 6/256 | 2/250 |
| Back painMusculoskeletal and connective tissue disorders | 3/630 | 6/589 | 2/256 | 7/250 |
| AnxietyPsychiatric disorders | 1/630 | 9/589 | 7/256 | 0/250 |
| VomitingGastrointestinal disorders | 3/630 | 13/589 | 3/256 | 0/250 |
| InsomniaPsychiatric disorders | 6/630 | 13/589 | 2/256 | 1/250 |
The Safety Analysis Set included all participants who were treated with any study drug.
| Age, Continuous(years) | IPX203 - Double-Blind Maintenance | IR CD-LD - Double -Blind Maintenance | Not Randomized | Total |
|---|---|---|---|---|
| Mean | 66.1 ± 9.02 | 66.5 ± 8.85 | 67.3 ± 9.00 | 66.5 ± 8.95 |
| Sex: Female, Male(Participants) | IPX203 - Double-Blind Maintenance | IR CD-LD - Double -Blind Maintenance | Not Randomized | Total |
|---|---|---|---|---|
| Female | 97 | 73 | 64 | 234 |
| Male | 159 | 177 | 60 | 396 |
| Ethnicity (NIH/OMB)(Participants) | IPX203 - Double-Blind Maintenance | IR CD-LD - Double -Blind Maintenance | Not Randomized | Total |
|---|---|---|---|---|
| Hispanic or Latino | 32 | 31 | 14 | 77 |
| Not Hispanic or Latino | 223 | 215 | 106 | 544 |
| Unknown or Not Reported | 1 | 4 | 4 | 9 |
| Race (NIH/OMB)(Participants) | IPX203 - Double-Blind Maintenance | IR CD-LD - Double -Blind Maintenance | Not Randomized | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 3 | 0 | 0 | 3 |
| Asian | 5 | 3 | 2 | 10 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 2 | 3 | 1 | 6 |
| White | 244 | 242 | 120 | 606 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 2 | 2 | 1 | 5 |
Showing the first 100 of 108 sites across 8 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Nov 2018 to primary completion in Jun 2021, 31 months.
Results were first posted in Feb 2023, 1 year 7 months after primary completion.
Of 39 industry-sponsored phase 3 interventional studies under Parkinson Disease, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 54. This study's 31 months is close to that.
Counting every sponsor, half of 67 studies reached it within 35 months; a quarter within 22 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: IPX203